Clinical trials: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Leukemia, Myelodysplastic Syndrome
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
The purpose of this research study is:(1) to determine if high doses of chemotherapy without total body irradiation can allow selected stem cells to take and grow,(2) to determine if selected stem cells from the blood or marrow…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
- Trial name
- NCT00582933
- Testing
- BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
- Trial name
- GVHD (NCT02117115)
- Testing
- Dynamic contrast-enhanced computed tomography, Ioversol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis
Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis
The hypothesis of the study is that according to modern data, the pathogenesis of multiple sclerosis is inextricably linked to the patient's microbiota.
- Trial name
- NCT04203017
- Testing
- allogeneic fecal microbiota
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Myeloid Leukemia or Myelodysplastic Syndromes
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with…
- Trial name
- NCT03931291
- Testing
- APR-246
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Aprea Therapeutics
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Sickle Cell Anemia, Cerebrovascular Accident
Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy
The aim of this study is to demonstrate that cerebral velocities assessed by transcranial doppler (TCD) are more significantly decreased by SCT than by long-term transfusion program A multicenter, national, non-randomized…
- Trial name
- DREPAGREFFE (NCT01340404)
- Testing
- Stem cell transplantation, Transfusion program
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study
The purpose of this study is to find out if a stem cell transplant is safe for patients with a very rare disease. The stem cell transplant is called AHSCT (for "allogeneic hematopoetic stem cell transplantation").
- Trial name
- MASS (NCT02427178)
- Testing
- Hematopoietic Allogeneic Stem Cells
- Sponsor
- Michio Hirano, MD
Myelofibrosis
Bone Marrow Transplant Chart Review for RIC
We will evaluate the records of 30 patients that have undergone allogeneic transplant, specifically looking at engraftment rate, relapse rate, disease free survival, overall survival, causes of death and other pertinent…
- Trial name
- NCT00723333
- Testing
- Reduced Intensity Conditioning (RIC) Allogenic Transplant
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Multiple Myeloma
Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
This study is a Phase I (non-randomized) study evaluating three dose-levels of Lenalidomide in patients after allogeneic stem cell transplantation, accomplished in two institutions (University Medical Center Hamburg-Eppendorf/…
- Trial name
- NCT00778752
- Testing
- Revlimid (Lenalidomide)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Primary Objective Evaluate the efficacy of sitagliptin in reducing the incidence of grade II-IV acute Graft Versus-Host Disease (GvHD) by day +100 post-transplant in patients undergoing allogeneic hematopoietic stem cell…
- Trial name
- NCT02683525
- Testing
- Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sherif S. Farag
Acute Myeloid Leukemia
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
To investigate the feasibility of delivering oral azacitidine (CC-486) as a consolidation regimen from the time of first complete remission (CR1), in patients with acute myelogenous leukemia (AML) eligible for curative intent…
- Trial name
- NCT06180863
- Testing
- oral azacitidine (CC-486)
- Where
- United States
- Sponsor
- Yale University
Vitamin D Deficiency
Vitamin D3 Supplementation for AlloHSCT-RCT
This study is to assess whether a single oral loading dose of 100,000 IU vitamin D3 prior to allogeneic hematopoietic stem cell transplant (aHSCT) can achieve optimal 25 hydroxy-vitamin D3(25-OH-D3) levels (>75nmol/L) at one…
- Trial name
- NCT03534674
- Testing
- vitamin D3
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- University of British Columbia
Leukemia, Myeloid, Acute
Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR
Hematopoietic stem cell transplantation in patients with newly diagnosed AML ≤60 years of age in intermediate risk, after first complete response in comparison to standard consolidation chemotherapy
- Trial name
- AML (NCT01246752)
- Testing
- Human Stem Cell Transplantation, Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
- Where
- 19 sites in Germany
- Volunteers
- 143 people
- Sponsor
- University Hospital Carl Gustav Carus
Hematologic Malignancies
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
The purpose of this research study is to determine if an experimental agent, LLME can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following blood (hematopoietic) stem cell transplantation
- Trial name
- NCT00429416
- Testing
- L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
GVHD - Graft-Versus-Host Disease, Infections After HSCT
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for people with severe blood-related diseases.
- Conditions
- GVHD - Graft-Versus-Host Disease, Infections After HSCT, Transplant Associated Microangiopathy TAM, Sinusoidal Obstruction Syndrome (SOS)
- Trial name
- NCT06715046
- Testing
- Sample collation for cfDNA methylation analysis, Sample collection for EV phenotype analysis
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Transplant-Related Disorder
Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model
To evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of child patients who are predicted to have a high risk for developing severe acute graftversus-host disease (aGVHD) by the dynamic aGVHD Onset…
- Trial name
- NCT05599256
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Vs Host Disease, Graft-versus-host-disease
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease, Prevention of aGVHD
- Trial name
- NCT04014790
- Testing
- RGI-2001, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Regimmune Corporation
Graft Versus Host Disease, Acute, Endothelial Dysfunction
Origin of CEC in Patients After Allo-HSCT
We believe that CEC, besides coming from cells shedding from patient vasculature, could partly belong to donor, originating from the cellular graft.
- Conditions
- Graft Versus Host Disease, Acute, Endothelial Dysfunction, Immune Tolerance
- Trial name
- DCEC-PIANO (NCT04038827)
- Testing
- D-CEC counting
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
This phase I trial tests the safety, side effects and best dose of NEXI-001 when given with decitabine and lymphodepleting chemotherapy in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Trial name
- NCT06572631
- Testing
- Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Hematological Malignancies
MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT
Allogeneic stem cell transplantation (allo-SCT) is a potent treatment, and sometimes the only curative treatment for aggressive hematological malignancies.
- Trial name
- PSCT19 (NCT02528682)
- Testing
- MiHA-loaded PD-L-silenced DC Vaccination
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.